Irish medical devices firm Technopath has announced a €3m investment in its quality control division in Tipperary, creating 40 new jobs.
The investment will go towards scaling the firm’s manufacturing capability and drive export activity, supported by Enterprise Ireland.
The quality control division manufactures products for a number of multinational in-vitro diagnostic companies. “Technopath’s breakthrough technology is the culmination of a five-year programme of research and development and €6m investment,” said Technopath co-founder Malcolm Bell. “We have developed a number of proprietary technologies, launching our first product in this division less than four years ago.”
Technopath’s long-term growth strategy is to develop niche, innovative, breakthrough technologies and to deploy these technologies worldwide, bringing the benefit of enhanced quality and cost savings to 20pc of patients around the world in the next two years.
“This is exemplified by our recent global product development, supply and distribution agreement with Abbott Diagnostics,” explained Bell. “Technopath is actively developing a number of additional innovative products for the global biopharmaceutical and dairy sectors that can address the significant un-met needs of these industries.”
“A central part of the Government’s plan for jobs and growth is creating a powerful engine of indigenous enterprise,” said Minister for Jobs, Enterprise and Innovation Richard Bruton, TD. “Over recent years we have established major strengths in key sectors such as ICT and life sciences – we must now build on this to get more indigenous companies growing to scale, exporting more and creating more jobs.”
